إعلان
إعلان
DSGN
Design Therapeutics, Inc. Common Stock
9.38
USDبرعاية
+0.21
+2.23%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
9.38
-0.01
-0.11%
تقارير أرباح DSGN
النسبة الإيجابية المفاجئة
DSGN تفوق 12 من 19 آخر التقديرات.
63%
التقرير التالي
بيانات التقرير القادم
٠٩ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.33
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/+10.00%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/+37.50%
Design Therapeutics, Inc. Common Stock earnings per share and revenue
On ٠٥ نوفمبر ٢٠٢٥, DSGN reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.35 USD, resulting in a 14.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 المحللين forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an زيادة of 10.00% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were Design Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Design Therapeutics, Inc. Common Stock reported EPS of -$0.30, beating estimates by 14.33%, and revenue of $0.00, 0% as expectations.
How did the market react to Design Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 4.89%, changed from $6.55 before the earnings release to $6.87 the day after.
When is Design Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٠٩ مارس ٢٠٢٦.
What are the forecasts for Design Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
المحللين, Design Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان